Laboratorios Rovi : Another impressive quarter to be reported, but guidance will be the focus
>Very strong numbers expected for Q4 by the consensus - The evolution of the coronavirus pandemic during Q4 2021 and the impact of the Omicron variant should have boosted Rovi’s manufacturing fees last quarter. We are raising our estimates for 2021 (EPS +10% leaving our long term estimates unchanged) to reflect a more robust scenario for the year and now expecting sales to jump +49%, EBITDA x2 to € 189m and €133m of net profit, similar to consensus expectations and ab...Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.